Evolent Health Inc
F:9EH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
E
|
Evolent Health Inc
F:9EH
|
US |
|
N
|
Nippon Steel Corp
F:NPS
|
JP |
|
Lisata Therapeutics Inc
F:8NE
|
US |
|
Fresh Del Monte Produce Inc
NYSE:DMC
|
KY |
|
O
|
Ossia International Ltd
SGX:O08
|
SG |
|
Saga Communications Inc
F:SGHB
|
US |
|
C
|
CNO Financial Group Inc
F:COS
|
US |
|
N
|
Nippon Steel Corp
XMUN:NPS
|
JP |
|
B
|
Broadstone Net Lease Inc
F:62XA
|
US |
|
P
|
Pandora A/S
XMUN:3P7
|
DK |
|
P
|
Pandora A/S
OTC:PANDY
|
DK |
|
E
|
Evonik Industries AG
SWB:EVK
|
DE |
|
N
|
Nippon Steel Corp
DUS:NPS
|
JP |
|
Stevva Corp
OTC:STVA
|
GR |
|
E
|
Evonik Industries AG
XMUN:EVK
|
DE |
|
E
|
Evonik Industries AG
F:EVK
|
DE |
|
D
|
DMG Mori Co Ltd
SWB:0MO
|
JP |
|
G
|
Global Water Resources Inc
TSX:GWR
|
US |
Wall St Price Targets
9EH Price Targets Summary
Evolent Health Inc
According to Wall Street analysts, the average 1-year price target for 9EH is 7.53 EUR with a low forecast of 3.36 EUR and a high forecast of 17.47 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is 9EH's stock price target?
Price Target
7.53
EUR
According to Wall Street analysts, the average 1-year price target for 9EH is 7.53 EUR with a low forecast of 3.36 EUR and a high forecast of 17.47 EUR.
What is the Revenue forecast for Evolent Health Inc?
Projected CAGR
21%
Over the last 12 years, the compound annual growth rate for Revenue has been 43%. The projected CAGR for the next 6 years is 21%.
What is the Gross Profit forecast for Evolent Health Inc?
Projected CAGR
8%
The compound annual growth rate for Gross Profit over the next 6 years is 8%.
